We are live on
!
Find out more
ACM
Altium Capital Management Portfolio holdings
AUM
$42M
This Fund
S&P 500
This Quarter
Est. Return
-9%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$353M
AUM Growth
+$12.9M
(+3.8%)
Cap. Flow
+$60.9M
Cap. Flow
% of AUM
17.29%
Top 10 Holdings %
Top 10 Hldgs %
42.16%
Holding
101
New
22
Increased
19
Reduced
17
Closed
34
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biohaven
BHVN
|
+$8.16M |
| 2 |
RxSight
RXST
|
+$7.8M |
| 3 |
Establishment Labs
ESTA
|
+$7.58M |
| 4 |
Capricor Therapeutics
CAPR
|
+$7.52M |
| 5 |
CMPS
Compass Pathways
CMPS
|
+$7.22M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vera Therapeutics
VERA
|
+$11.2M |
| 2 |
Vaxcyte
PCVX
|
+$8.23M |
| 3 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$6.49M |
| 4 |
iRhythm Holdings
IRTC
|
+$6.38M |
| 5 |
Sarepta Therapeutics
SRPT
|
+$5.27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91% |
| 2 | Consumer Staples | 0.08% |
| 3 | Consumer Discretionary | 0% |
| 4 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CPRX
26
DELISTED
Catalyst Pharmaceutical
CPRX
| $5.32M | 1.51% |
255,000
-130,000
| -34% | -$2.79M |
|
|
CTNM
27
Contineum Therapeutics
CTNM
$577M
| $4.89M | 1.39% |
334,000
-35,126
| -10% | -$556K |
|
28
Syndax Pharmaceuticals
SNDX
$1.76B
| $4.89M | 1.39% |
+370,000
| New | +$6.33M |
|
29
Savara
SVRA
$1.19B
| $4.85M | 1.37% |
1,579,000
+4,000
| +0.3% | +$13.9K |
|
|
AVDL
30
DELISTED
Avadel Pharmaceuticals
AVDL
| $4.76M | 1.35% |
452,475
-157,525
| -26% | -$1.91M |
|
31
Corbus Pharmaceuticals
CRBP
$180M
| $4.54M | 1.29% |
385,000
+190,000
| +97% | +$3.19M |
|
32
Arrowhead Research
ARWR
$12.1B
| $4.33M | 1.23% |
230,257
-124,743
| -35% | -$2.57M |
|
|
AVR
33
Anteris Technologies
AVR
$814M
| $4.11M | 1.17% |
+737,000
| New | +$4.12M |
|
|
PROF
34
Profound Medical
PROF
$289M
| $3.64M | 1.03% |
+485,000
| New | +$3.72M |
|
35
Xtant Medical Holdings
XTNT
$62.1M
| $3.29M | 0.93% |
7,415,413
| – | – |
|
36
Skye Bioscience
SKYE
$16.6M
| $3.22M | 0.91% |
1,139,000
-176,146
| -13% | -$736K |
|
37
Oric Pharmaceuticals
ORIC
$1.34B
| $2.86M | 0.81% |
355,000
| – | – |
|
38
TG Therapeutics
TGTX
$7.59B
| $2.86M | 0.81% |
+95,000
| New | +$2.73M |
|
39
Nektar Therapeutics
NKTR
$2.48B
| $2.79M | 0.79% |
200,000
+199,239
| +26,181% | +$3.51M |
|
40
Keros Therapeutics
KROS
$211M
| $2.77M | 0.79% |
175,000
+106,000
| +154% | +$5.51M |
|
41
PUT
AnaptysBio
ANAB
$1.62B
| $2.73M | 0.77% |
+206,200
| New | +$4.99M |
|
42
ImmunityBio
IBRX
$7.76B
| $2.71M | 0.77% |
+1,060,000
| New | +$4.42M |
|
43
Lexeo Therapeutics
LXEO
$357M
| $2.66M | 0.76% |
+405,000
| New | +$3.19M |
|
|
TERN
44
DELISTED
Terns Pharmaceuticals
TERN
| $2.63M | 0.75% |
475,000
+145,000
| +44% | +$982K |
|
45
Revolution Medicines
RVMD
$42.1B
| $2.62M | 0.74% |
+60,000
| New | +$3.03M |
|
|
EPIX
46
DELISTED
ESSA Pharma
EPIX
| $2.56M | 0.73% |
+1,428,000
| New | +$4.55M |
|
47
Alphatec Holdings
ATEC
$1.42B
| $2.43M | 0.69% |
+264,562
| New | +$2.11M |
|
48
Larimar Therapeutics
LRMR
$436M
| $1.95M | 0.55% |
505,000
-188,000
| -27% | -$1.24M |
|
|
OKUR
49
OnKure Therapeutics
OKUR
$168M
| $1.88M | 0.53% |
+218,386
| New | +$3.31M |
|
|
ACOG
50
Alpha Cognition
ACOG
$189M
| $1.62M | 0.46% |
+275,000
| New | +$1.54M |
|
Similar funds
TA
SIM
VEPM
VI
BCM
VAM
SCM
CAS
Altium Capital Management's Q4 2024 Portfolio in Review
As of Q4 2024, Altium Capital Management held 101 positions worth $353M, up 3.8% from $340M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Altium Capital Management deployed $60.9M of net new capital in Q4 2024, opening 22 new positions and adding to 19 existing holdings. Its largest new stake was Compass Pathways: 1,424,400 shares worth $5.38M.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 97% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
On the sell side, the largest reduction was Vera Therapeutics, an estimated $11.2M trimmed.
- Altium Capital Management's largest Q4 2024 buy was Compass Pathways: 1,424,400 shares worth $5.38M.
- Altium Capital Management added most to Biohaven in Q4 2024, an estimated $8.16M increase.
- Altium Capital Management's biggest Q4 2024 reduction was Vera Therapeutics, cutting an estimated $11.2M.
- Altium Capital Management fully exited Vaxcyte in Q4 2024, selling an estimated $8.23M.
- Altium Capital Management's ten largest holdings make up 42% of its $353M portfolio in Q4 2024.
- Altium Capital Management opened 22 new positions and closed 34 in Q4 2024.
- Altium Capital Management's portfolio value rose 3.8% quarter-over-quarter to $353M.
Based on Altium Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.